Gastrointestinal Stromal Tumors Market Gains Momentum by Striking Growth Rate with Top Vendors F. Hoffmann-La Roche Ltd, AB SCIENCES and Boston Biomedical Forecasts Till 2023

The Global Gastrointestinal Stromal Tumors Market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global gastrointestinal stromal tumors market is expected to register at a CAGR ~ 7 % during the forecast period of 2018–2023.

A Gastrointestinal Stromal Tumor (GIST) is a type of tumor which occurs in the gastrointestinal tract and most commonly in the stomach or small intestine. These tumors grow from specialized cells found in the gastrointestinal tract called Interstitial Cells of Cajal (ICC) or precursors to these cells. GIST affects an estimated 11 to 20 patients per million per year worldwide.

GISTs are rare cancers known as soft tissue sarcomas. These tissue sarcomas develop in supporting and connective tissues. These GIST accounts for around 20% of soft tissue sarcomas and is the most common mesenchymal tumors affecting the gastrointestinal tract. Treatment of GIST is largely dependent on the size of the tumor, position, and development rate, and is most commonly removed through the procedure of surgical resection and targeted therapies.

The growth of this market is due to increasing prevalence of gastrointestinal diseases, increasing the prevalence of cancer, increasing investments and funding in the field of life science research, increasing awareness among the people, growing geriatric population, changing reimbursement policies and various others.

Get Exclusive Sample Copy @ https://www.marketresearchfuture.com/sample_request/1583 .

Segmentation

The global gastrointestinal stromal tumors market is segmented on the basis of the indication, diagnosis, treatment, and end-user.

On the basis of indication, the market is classified into stomach, small intestine, large intestine (colon), and other indications.

On the basis of diagnosis, the market is segmented into imaging studies, plain abdominal radiography, barium and air (double-contrast) series, computed tomography scans of the abdomen and pelvis, magnetic resonance imaging, endoscopy, endoscopic ultrasonography, and others.

The global gastrointestinal stromal tumors market on the basis of treatment is segmented into surgery, targeted therapy, radiation therapy, chemotherapy, ablation, embolization and others. Targeted therapy is further segmented into Tyrosine kinase inhibitors (TKIs), Imatinib, Sunitinib, Regorafenib, and others. While, ablation is segmented into Radiofrequency ablation (RFA), ethanol (alcohol) ablation, microwave thermotherapy, cryosurgery (cryotherapy), and others.

On the basis of end-user, the global gastrointestinal stromal tumors market is segmented into hospitals & clinics, ambulatory surgical centers, and others.

Geographically, the market has been segmented into America, Europe, Asia Pacific, and the Middle East & Africa. The Americas gastrointestinal stromal tumors market is further segmented into North America, and South America. North America is further classified as the U.S. and Canada.

The European gastrointestinal stromal tumors market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, the U.K., Italy, Spain, and the Rest of Western Europe.

The Asia Pacific gastrointestinal stromal tumors market is segmented into Japan, China, India, Republic of Korea, Australia, and the Rest of Asia Pacific.

The Middle East & Africa gastrointestinal stromal tumors market is segmented into the Middle East and Africa.

Regional Market Summary

Globally, the American region is the largest market for gastrointestinal stromal tumors owing to the increasing occurrence of liver cancer, the presence of major manufacturers in the region, and the development for the products. Moreover, increasing presence of genetic disorders in the U.S., robust healthcare infrastructure, availability of exclusive medical facilitates for caretaking of patients suffering from inoperable cancers will continue to drive the growth of the American gastrointestinal stromal tumor market.

Europe accounted for the second largest share in global gastrointestinal stromal tumors market in 2017. Growing number of cases of gastrointestinal stromal tumors is a major driving force of this market. Approximately 11 to 20 people per million worldwide are diagnosed with GIST each year, and in Europe, there are an estimated 15 people per million living with GIST.

Asia Pacific is expected to be the fastest growing market for gastrointestinal stromal tumors market owing to the developing healthcare facilities, increasing awareness, and changing healthcare facilities. Moreover, major companies are grabbing these opportunities and expanding their presence in the region. Furthermore, increasing research and development in this region has further enhanced the growth of the market.

The Middle East & Africa also shows a steady rise in the market owing to limited availability of medical facilities, and to the lack of knowledge in the medical sector. Global Gastrointestinal Stromal Tumors Market, by Indication

Stomach
Small intestine
Large intestine (colon)
Other indications
Global Gastrointestinal Stromal Tumors Market, by Diagnosis

Imaging studies
Plain abdominal radiography
Barium and air (double-contrast) series
Computed tomography scans of the abdomen and pelvis
Magnetic resonance imaging
Endoscopy
Endoscopic ultrasonography
Others
Get Discount @ https://www.marketresearchfuture.com/check-discount/1583 .

Global Gastrointestinal Stromal Tumors Market, by Treatment

Surgery
Targeted therapy
Tyrosine Kinase Inhibitors (TKIS)
Imatinib
Sunitinib
Regorafenib
Others
Radiation therapy
Chemotherapy
Ablation
Radiofrequency Ablation (RFA)
Ethanol (alcohol) ablation
Microwave thermotherapy
Cryosurgery (cryotherapy)
Others
Embolization
Others
Global Gastrointestinal Stromal Tumors Market, by End-user

Hospitals & Clinics
Ambulatory surgical centers
Others
Key Players

Some of the key players in the global gastrointestinal stromal tumors market are Bayer AG (Germany) Novartis AG (Switzerland), Immunicum AB (Sweden), F. Hoffmann-La Roche Ltd.(Switzerland), AB SCIENCES (FRANCE), Arog Pharmaceuticals, Inc. (U.S), Boston Biomedical, Inc. (U.S), Sun Pharmaceutical Industries Limited (India), (U.S), Pfizer Inc. (U.S), and NATCO Pharma Limited (U.S), and others.

Research Methodology

Market Research Future research is conducted by industry experts who offer insight into industry structure, market segmentation, Treatment assessment, competitive landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments & categories geographically presented are studied and are estimated based on primary & secondary research.

Global Gastrointestinal Stromal Tumors Market, by Region

Americas
North America
U.S.
Canada
South America
Europe
Western Europe
Germany
France
Italy
Spain
U.K.
Rest of Western Europe
Eastern Europe
Asia Pacific
Japan
China
India
Australia
Republic of Korea
Rest of Asia Pacific
The Middle East & Africa
Middle East
Africa
Continued….!

Browse Complete Report @ https://www.marketresearchfuture.com/reports/gastrointestinal-stromal-tumors-market-1583 .

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.